Patient Medication Information: uses, side effects, how to take - Act Docetaxel 40 mg/mL
ABOUT THIS MEDICATION
What the medication is used for:
ACT Docetaxel 40 mg/mL is used as or for the:
- adjuvant treatment of patients with operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide
- advanced or metastatic breast cancer, as single agent, or in combination with doxorubicin; or in combination with capecitabine (Xeloda®) after failure of previous anti-cancer drugs
- advanced or metastatic non small cell lung cancer, as single agent or in combination with platinum derivatives
- metastatic ovarian cancer after failure of previous anti-cancer drugs
- metastatic prostate cancer in combination with prednisone or prednisolone
- recurrent or metastatic squamous cell carcinoma of the head and neck after failure of previous anti-cancer drugs
What it does:
Here’s how ACT Docetaxel 40 mg/mL works: Every cell in your body contains a supporting structure (almost like a “skeleton”). If this “skeleton” is changed or damaged, the cell can’t grow or reproduce.
ACT Docetaxel 40 mg/mL makes the “skeleton” in cells unnaturally stiff. The cancer cells then can no longer grow or reproduce.
When it should not be used:
ACT Docetaxel 40 mg/mL should not be used if:
- you have had an allergic reaction to docetaxel or to polysorbate 80 or any of the other ingredients in the product;
- you have a low white blood cell count (neutropenia);
- you have a severe liver disease;
you are pregnant or breast-feeding
What the medicinal ingredient is:
The active ingredient in ACT Docetaxel 40 mg/mL is docetaxel.
What the nonmedicinal ingredients are:
The non-active ingredients are polysorbate and ethanol.
What dosage forms it comes in:
ACT Docetaxel 40 mg/mL is available in a concentrated solution for injection, packaging in a vial of 20 mg/0.5 mL or 80 mg/2 mL.
WARNINGS AND PRECAUTIONS
Serious Warnings and Precautions
ACT Docetaxel 40 mg/mL should be given under the supervision of a doctor experienced in the use of anti-cancer drugs. ACT Docetaxel 40 mg/mL should not be used in patients with white blood cell (neutrophil) counts of less than 1,500 cells/mm3. ACT Docetaxel 40 mg/mL may cause severe allergic reactions which require immediate discontinuation of the drug. A possible serious side effect that may occur is acute myeloid leukemia. No studies have been conducted to assess the carcinogenic potential of ACT Docetaxel 40 mg/mL. |
|---|
BEFORE your ACT Docetaxel 40 mg/mL injection, talk to your doctor if
- you are pregnant or planning to get pregnant
- you have not taken your premedication as directed
Patients receiving ACT Docetaxel 40 mg/mL may experience:
- Fluid retention. Your doctor will prescribe you medication to reduce the risk of having severe fluid retention.
- Low blood cell count: Your doctor will need to check your blood at regular visits while you are using this medicine. Be sure to go to all your appointments. Your doctor may decide to reduce your dose if your white blood cell count is low.
- Allergic reactions: Allergic reactions may occur within a few minutes following the initiation of ACT Docetaxel 40 mg/mL. Severe allergic reactions with severe rash, difficulty in breathing (bronchospasm), low blood pressure (hypotension) may occur. Your doctor will prescribe you medication to reduce the risk of having an allergic reaction.
- Nerve pain (peripheral neurotoxicity): Some people feel this pain as numbness, tingling, or burning in their hands and feet. This nerve pain is rarely severe and usually goes away after treatment is completed. In some cases, your doctor may decide to reduce your dose or stop your treatment.
- Rash: This usually occurs on the feet and hands, but may also appear on the arms, face or body. The rash is rarely serious, and it is rare for a patient to discontinue ACT
- Docetaxel 40 mg/mL therapy because of rash or other skin problems. In some cases, your doctor may decide to reduce your dose.
INTERACTIONS WITH THIS MEDICATION
There is a possible drug interaction between ACT Docetaxel 40 mg/mL and the following drugs:
- cyclosporine
- terfenadine
- ketoconazole
- erythromycin
- protease inhibitors (e.g. ritonavir)
Tell your doctor if you are taking any medicine which has been prescribed for you or which you bought without a prescription.
PROPER USE OF THIS MEDICATION
How often will I get treated with ACT Docetaxel 40 mg/mL?
ACT Docetaxel 40 mg/mL is usually given in a 1-hour intravenous (IV) dose every 21 days. Every patient is different; your doctor will determine what dose of ACT Docetaxel 40 mg/mL is right for you and how often you should receive it.
Your doctor may prescribe ACT Docetaxel 40 mg/mL either alone or in combination with other anti-cancer drugs, such as doxorubicin, cyclophosphamide, platinum derivatives (cisplatin, carboplatin), capecitabine (Xeloda®), prednisone or prednisolone.
What do I need to do before each ACT Docetaxel 40 mg/mL treatment?
The administration of ACT Docetaxel 40 mg/mL requires you to take medication before each treatment begins. Every time you receive ACT Docetaxel 40 mg/mL, you will be asked to take some premedication; the purpose of this premedication is to reduce the fluid retention you may experience during treatment. Usually, the premedication consists of corticosteroid pills that are taken orally one day before each ACT Docetaxel 40 mg/mL treatment, on the same day of each treatment, and one day after each treatment. Your doctor or nurse will tell you exactly what premedication you need to take and for how long.
Your doctor may also decide to give you other medications to reduce the risk of infection.
If you forget to take your premedication as directed, make sure to tell your doctor or nurse before you get your ACT Docetaxel 40 mg/mL treatment.
Overdose:
| In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms. |
Missed Dose:
This medicine needs to be given on a fixed schedule. If you miss an appointment, call your doctor for instructions.
SIDE EFFECTS AND WHAT TO DO ABOUT THEM
Like many anti-cancer drugs, ACT Docetaxel 40 mg/mL may have side effects. Most of the side effects that occur with ACT Docetaxel 40 mg/mL are manageable. Occasionally, it is necessary to stop the treatment. If you do experience side effects, your doctor can give you a number of medications and explain techniques to help make you feel more comfortable.
The most common side effects are:
- Nausea, diarrhea, vomiting
- Fatigue
- Stomatitis: sores in the mouth
- Nail changes
- Low white blood cell count (neutropenia)
- Fever
- Hair Loss
- Weakness
- Rash
- Nerve pain
- Fluid retention
- Swelling at the injection site
Low White Blood Cell Count: Your white blood cells protect your body against infection. There are three types of white blood cells; the most important in preventing infections are cells called neutrophils. Many anti-cancer drugs, including ACT Docetaxel 40 mg/mL, cause a temporary drop in neutrophils (a condition known as neutropenia); however, most people receiving ACT Docetaxel 40 mg/mL do not develop infections, even when they have neutropenia. Your doctor will be checking routinely your white blood count and will alert you if your white count is low.
Fever is one of the most common signs of infection. So if you have a fever, make sure to tell your doctor or nurse immediately.
Hair Loss: Loss of the hair (including eyebrows, eyelashes, pubic hair, underarm hair and the hair on your head), which is known as alopecia, occurs in most patients taking ACT Docetaxel 40 mg/mL. Hair loss may happen shortly after treatment has begun. Your hair should grow back once you’ve finished the treatment. However, some patients may experience persistent hair loss. In the meantime, your doctor or nurse can probably refer you to a special store that carries turbans and wigs specifically for patients with cancer.
Weakness: Many patients receiving ACT Docetaxel 40 mg/mL experience a feeling of weakness during their treatment. If weakness is accompanied by joint or muscle pain, make sure to tell your doctor or nurse; your doctor can prescribe pain medication to help make you feel more comfortable.
Rash: Patients on ACT Docetaxel 40 mg/mL may develop a rash. This usually occurs on the feet and hands, but may also appear on the arms, face or body. The rash generally appears within a week after each ACT Docetaxel 40 mg/mL treatment, and disappears again before the next treatment. The rash is rarely serious, and it is rare for a patient to discontinue ACT Docetaxel 40 mg/mL therapy because of rash or other skin problems.
Nerve Pain: Patients receiving ACT Docetaxel 40 mg/mL may experience nerve pain; some people feel this pain as numbness, tingling, or burning in their hands and feet. This nerve pain is rarely severe and usually goes away after treatment is completed. However, if you are bothered by nerve pain, make sure to tell your doctor or nurse; your doctor can prescribe pain medication to help make you feel more comfortable.
Fluid Retention: Fluid retention can occur in patients receiving ACT Docetaxel 40 mg/mL. It may begin as swelling on the legs. Your doctor will prescribe medication, which is important for you to take to reduce the likelihood that the fluid retention will be serious or cause your treatment to be discontinued.
Blurred vision: In case of vision problems, you should have a complete eye and vision examination. If cystoid macular edema (blurred vision due to swelling of the retina within the eye) is diagnosed, your doctor may stop your treatment.
When ACT Docetaxel 40 mg/mL is used in combination with capecitabine (Xeloda®), the frequency of side effects may differ. In particular, the risk of developing a rash of the hands and feet is increased. You should refer to your doctor for more details.
| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | ||||||
|---|---|---|---|---|---|---|
| Symptom / effect | Talk with your doctor or pharmacist | Stop taking drug and seek immediate emergency medical attention | ||||
| Only if severe | In all cases | |||||
| Common | ||||||
| Muscle pain | √ | |||||
| Nerve pain such as numbness, tingling, or burning in their hands and feet | √ | |||||
| Weakness | √ | |||||
| Uncommon | ||||||
| Allergic reactions such as trouble breathing, tightness in the throat, rash, hives, swelling of the lips or tongue or low blood pressure | √ | |||||
| Fever or signs of infection, like redness or swelling at the injection site, a cough that brings up mucus, or a sore throat | √ | |||||
| Irregular or rapid heart rate | √ | |||||
| Liver problems such as loss of | ||||||
| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM |
|---|
| Symptom / effect | Talk with your doctor or pharmacist | Stop taking drug and seek immediate emergency medical attention |
|---|
| Only if severe | In all cases | ||
|---|---|---|---|
appetite, dark urine, light-colored stools, yellowing of the skin or eyes | √ | ||
| Kidney problems | √ | ||
| Persistent vomiting or diarrhea | √ | ||
| Visual disturbances | √ | ||
This is not a complete list of severe side effects. If you have any unexpected effects while taking this drug, contact your doctor or pharmacist.
HOW TO STORE IT
The unopened vials should be stored between 2°C and 25°C in their original packaging. Protect from light.
REPORTING SUSPECTED SIDE EFFECTS
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect. NOTE: Should you require information related to the management of side effects, please contact your health care provider before notifying Canada Vigilance.. The Canada Vigilance Program does not provide medical advice. |
MORE INFORMATION
Your doctor, pharmacist and nurse are always your best source of information about your condition and treatment. If you have additional questions or concerns, be sure to ask them.
This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Actavis Pharma Company, at 1-866-254-6111
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, ON
Canada, L5N 6J5
Prepared on: May 26, 2015